Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: At a mean follow-up of 4.5 years (range, 2 to 7 years), 23 patients (52%) remain event-free, 20 have relapsed (45%), and one has died of chemotherapy-related toxicity. The 5-year event-free survival and overall survival were 54.2% and 62.7%, respectively. To assess the prognostic significance of neural differentiation in the family of Ewing's sarcoma, these results have been compared with the outcomes of 138 concomitant patients with typical Ewing's sarcoma ( TES) who were treated according to the same protocol. Of these, 103 (75%) remained continuously event-free, 34 (24%) relapsed, and one died of chemotherapy-related toxicity. It follows that PNET patients treated with this chemotherapy regimen have a significantly worse prognosis than typical ES patients (5-year event-free survival, 54.2% v 70.6%, P <.012; 5-year overall survival, 62.7% v 78.3%, P <.002). CONCLUSION: The authors conclude that studies into new adjuvant therapy for Ewing's sarcoma modulated according to risk of relapse should also consider neural differentiation as a risk factor.
|
Authors | G Bacci, S Ferrari, F Bertoni, D Donati, P Bacchini, A Longhi, A Brach Del Prever, C Forni, S Rimondini |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 18
Issue 4
Pg. 885-92
(Feb 2000)
ISSN: 0732-183X [Print] United States |
PMID | 10673532
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents, Alkylating
- Antineoplastic Agents, Phytogenic
- Dactinomycin
- Vincristine
- Doxorubicin
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects)
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Neoplasms
(drug therapy, radiotherapy, surgery)
- Chi-Square Distribution
- Cyclophosphamide
(administration & dosage, adverse effects)
- Dactinomycin
(administration & dosage, adverse effects)
- Disease-Free Survival
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Humans
- Male
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
(pathology)
- Neuroectodermal Tumors, Primitive, Peripheral
(drug therapy, radiotherapy, surgery)
- Prognosis
- Radiotherapy, Adjuvant
- Sarcoma, Ewing
(drug therapy, radiotherapy, surgery)
- Survival Rate
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|